drugset / Trial / NCT02647762
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.
Timeline
- Start
- 2017-10-30
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MTX | Unknown | 20 mg | — |
| Subject | Piclidenoson | Small molecule | 1 mg | Oral |
| Subject | Piclidenoson | Small molecule | 2 mg | Oral |